Summary
65 / 100 · Bulios Score
What speaks for it
- Out of every 100 JPY of revenue, 9.9 JPY is left as net profit.
- It holds more cash than debt: ¥40.1B against ¥37.0B.
- You pay 11.3 JPY for 1 JPY of yearly profit, little for its sector.
- It bought back its own shares for ¥14.4B in the last fiscal year, 3.0% of its market value.
What to watch
- Revenue growth is slowing: 5.2% a year over the last 3 years against 169% over 5 years.
- Earnings per share swing sharply from year to year.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 11.3 JPY for 1 JPY of yearly profit.
Valuation in detailIs it growing?
SlowlyRevenue (JPY)
Diluted EPS (JPY)
- Analyst estimate
Revenue grew by 169% a year over 5 years. Over the last 3 years it grew by 5.2% a year. Earnings per share fell by 6.0% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 JPY of revenue goes
- Cost of sales 70 JPY
- Sales and administration 20 JPY
- Taxes and other -0.5 JPY
- Net profit 9.9 JPY
Net profit, industry median (Chemicals - Specialty) 5.9 JPY
Out of every 100 JPY of revenue, 9.9 JPY is left as net profit.
Profitability in detailIs it financially healthy?
YesIt holds more cash than debt.
Financial health in detailDoes it pay a dividend?
Moderate, at risk- Yield
- 2.57%
- Paid out of profit
- 29%
You receive $0.40 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.